167 related articles for article (PubMed ID: 34153143)
21. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
22. Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial.
Francke MI; Andrews LM; Le HL; van de Wetering J; Clahsen-van Groningen MC; van Gelder T; van Schaik RHN; van der Holt B; de Winter BCM; Hesselink DA
Clin Pharmacol Ther; 2021 Jul; 110(1):169-178. PubMed ID: 33452682
[TBL] [Abstract][Full Text] [Related]
23. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene.
Enokiya T; Nishikawa K; Hamada Y; Ikemura K; Sugimura Y; Okuda M
Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):525-533. PubMed ID: 33248001
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
25. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
26. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
[TBL] [Abstract][Full Text] [Related]
27. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
28. Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype.
Lloberas N; Hesselink DA; van Schaik RH; Grinyò JM; Colom H; Gelder TV; Elens L
Pharmacogenomics; 2018 Mar; 19(4):305-310. PubMed ID: 29469606
[TBL] [Abstract][Full Text] [Related]
29. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
30. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
31. Anti-Interleukin 6 Therapeutics for Chronic Antibody-Mediated Rejection In Kidney Transplant Recipients.
Sharma R
Exp Clin Transplant; 2022 Aug; 20(8):709-716. PubMed ID: 34981708
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
Muduma G; Odeyemi I; Pollock RF
J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
[TBL] [Abstract][Full Text] [Related]
33. New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment.
Mayer KA; Doberer K; Eskandary F; Halloran PF; Böhmig GA
Curr Opin Organ Transplant; 2021 Feb; 26(1):97-105. PubMed ID: 33315763
[TBL] [Abstract][Full Text] [Related]
34. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
[TBL] [Abstract][Full Text] [Related]
35. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
36. Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.
Berger M; Baliker M; Van Gelder T; Böhmig GA; Mannon RB; Kumar D; Chadban S; Nickerson P; Lee LA; Djamali A
Transplantation; 2024 May; 108(5):1109-1114. PubMed ID: 37941113
[TBL] [Abstract][Full Text] [Related]
37. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials.
Mayer KA; Budde K; Jilma B; Doberer K; Böhmig GA
Expert Opin Emerg Drugs; 2022 Jun; 27(2):151-167. PubMed ID: 35715978
[TBL] [Abstract][Full Text] [Related]
39. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
Roy JN; Barama A; Poirier C; Vinet B; Roger M
Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
[TBL] [Abstract][Full Text] [Related]
40. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
